Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet
Trial Snapshot
- Phase
- Phase 1
- Status
- Enrolling By Invitation
- Sponsor
- Johns Hopkins University
- Enrollment
- 22
- Locations
- 1
- Primary Endpoint
- Statin Adherence
Study Overview
Brief Summary
Ketogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications. However, KDT use can lead to increased cholesterol levels in some adults with epilepsy (AWE). Treatments that can reverse elevations in cholesterol observed with long-term KDT use without compromising diet adherence and seizure control are needed. The proposed study will explore the feasibility and safety of diet modification and statin use to lower cholesterol in this population. Study findings will help guide doctors utilizing KDTs in adults with epilepsy on how to approach managing elevations in cholesterol.
Detailed Description
The scientific premise of this proposal is that established or long-term (≥ 12 months) Modified Atkins diet (MAD) use in AWE influences atherosclerotic cardiovascular disease (ASCVD) risk and can be modified to reduce dyslipidemia when observed. Hence, the overarching goals of this proposal are to explore the safety and feasibility of dyslipidemia management strategies to reduce ASCVD risk in AWE on MAD without increasing seizure risk. This study will collect data before and after randomly assigned interventions to reduce LDL in AWE on long-term MAD recruited from patients receiving clinical care in the Johns Hopkins Adult Epilepsy Diet Center.
AWE with dyslipidemia on long-term MAD will be randomized 1:1 to either MAD modification (10% reduction of dietary energy from saturated fat, replaced with poly-unsaturated fat ) or moderate-intensity statin use (atorvastatin 10mg) for 12 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Modified Atkins Diet use ≥ 12 months
- •Dyslipidemia based on American College of Cardiology/American Heart Association guidelines (i.e., LDL ≥190 mg/dL, 10-year ASCVD risk ≥5% with risk enhancers, etc.)
- •18 years of age or older
- •Body mass index (BMI) > 18.5
- •Stable anti-seizure medication regimen for > 1 month.
Exclusion Criteria
- •< 18 years of age
- •Body mass index (BMI) < 18.5
- •Changes in anti-seizure medication regimen < 1 month prior to participation
- •Known ASCVD (history of acute coronary syndrome, myocardial infarction, angina, stroke, transient ischemic attack, or peripheral artery disease)
- •Current statin medication use
- •Prior serious adverse response to atorvastatin or other statin medications
- •Uncorrected carnitine deficiency
Arms & Interventions
Statin
Participants will receive 10mg of atorvastatin daily for 12 weeks
Intervention: Atorvastatin 10mg (Drug)
Modified Atkins diet (MAD) Modification
Participants will be instructed on how to change their modified Atkins diet for 12 weeks. They will replace 10% of daily dietary energy from saturated fat with poly-unsaturated fat.
Intervention: Modification of dietary fat composition (Other)
Outcomes
Primary Outcomes
Statin Adherence
Time Frame: 12 weeks
Statin adherence will be determined based on pills returned at study completion, with participants labeled adherent if 80% or more of pills were consumed.
Diet adherence as assessed by 3 day food records
Time Frame: 12 weeks
Diet adherence will be based on the ability to achieve 10% reduction in dietary energy from saturated fat assessed from 3-day food records, the gold standard for diet intake assessments.
Change in weekly seizure frequency
Time Frame: 12 weeks
12-week difference in weekly seizure frequency from baseline
LDL Change
Time Frame: 12 weeks
12-week % LDL change from baseline within arms and between arms
Seizure severity questionnaire score
Time Frame: 12 weeks
12-week difference in seizure severity questionnaire (SSQ) score (score 1-7, with higher score indicating more severe seizures)
Secondary Outcomes
- Blood ketone change(12 weeks)
- Frequency of adverse events(12 weeks)